|
MAT2A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.62709853871002E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.58609825063172E-11 |
| Normal-vs-Stage2 |
3.14080000007877E-07 |
| Normal-vs-Stage3 |
4.73321382088443E-12 |
| Normal-vs-Stage4 |
3.50030004980795E-09 |
| Stage1-vs-Stage2 |
2.967200E-01 |
| Stage1-vs-Stage3 |
1.099180E-01 |
| Stage1-vs-Stage4 |
4.403200E-01 |
| Stage2-vs-Stage3 |
5.925600E-02 |
| Stage2-vs-Stage4 |
2.140600E-01 |
| Stage3-vs-Stage4 |
8.977200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.94150251431324E-11 |
| Normal-vs-AfricanAmerican |
3.019100E-03 |
| Normal-vs-Asian |
6.87739865057324E-11 |
| Caucasian-vs-AfricanAmerican |
1.668790E-01 |
| Caucasian-vs-Asian |
7.991800E-01 |
| AfricanAmerican-vs-Asian |
1.542430E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.6341155619275E-12 |
| Normal-vs-Female |
6.11960482288509E-11 |
| Male-vs-Female |
1.909810E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.58739712883016E-11 |
| Normal-vs-Age(41-60Yrs) |
1.00808250635964E-13 |
| Normal-vs-Age(61-80Yrs) |
4.0579983817679E-11 |
| Normal-vs-Age(81-100Yrs) |
6.760000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.988800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.525800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.607800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.209200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.528800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.319400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.16889997681113E-09 |
| Classical-VS-Follicular |
6.934100E-02 |
| Classical-VS-Other |
2.369200E-01 |
| Classical-VS-Normal |
1.09540043702339E-10 |
| Tall-VS-Follicular |
3.35079997082488E-09 |
| Tall-VS-Other |
4.806200E-01 |
| Tall-VS-Normal |
1.62492241884138E-12 |
| Follicular-VS-Other |
9.655600E-02 |
| Follicular-VS-Normal |
6.9405999947314E-08 |
| Other-VS-Normal |
1.24609999996306E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.18159975932053E-11 |
| Normal-vs-N1 |
4.60790000000877E-06 |
| N0-vs-N1 |
6.056600E-01 |
|
|
